Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Dec 9;6(3):559-567.
doi: 10.1159/000450601. eCollection 2016 Sep-Dec.

Brain-Derived Neurotrophic Factor Serum Levels and Hippocampal Volume in Mild Cognitive Impairment and Dementia due to Alzheimer Disease

Ericksen Mielle Borba  1 , Juliana Avila Duarte  2 , Giovana Bristot  3 , Ellen Scotton  3 , Ana Luiza Camozzato  4 , Márcia Lorena Fagundes Chaves  5
Affiliations

Brain-Derived Neurotrophic Factor Serum Levels and Hippocampal Volume in Mild Cognitive Impairment and Dementia due to Alzheimer Disease

Ericksen Mielle Borba et al. Dement Geriatr Cogn Dis Extra. .

Abstract

Background/aims: Hippocampal atrophy is a recognized biomarker of Alzheimer disease (AD) pathology. Serum brain-derived neurotrophic factor (BDNF) reduction has been associated with neurodegeneration. We aimed to evaluate BDNF serum levels and hippocampal volume in clinical AD (dementia and mild cognitive impairment [MCI]).

Methods: Participants were 10 patients with MCI and 13 with dementia due to AD as well as 10 healthy controls. BDNF serum levels were determined by ELISA and volumetric measures with NeuroQuant®.

Results: MCI and dementia patients presented lower BDNF serum levels than healthy participants; dementia patients presented a smaller hippocampal volume than MCI patients and healthy participants.

Discussion: The findings support that the decrease in BDNF might start before the establishment of neuronal injury expressed by the hippocampal reduction.

Keywords: Alzheimer disease; Blood biomarker; Brain atrophy; Hippocampus; Mild cognitive impairment.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Barnes J, Bartlett JW, van de Pol LA, Loy CT, Scahill RI, Frost C, Fox NC. A meta-analysis of hippocampal atrophy rates in Alzheimer's disease. Neurobiol Aging. 2009;30:1711–1723. - PMC - PubMed
    1. Jack CR, Jr, Bernstein MA, Fox NC, Thompson P, Alexander G, Harvey D, Borowski B, Britson PJ, L Whitwell J, Ward C, Dale AM, Felmlee JP, Gunter JL, Hill DL, Killiany R, Schuff N, Fox-Bosetti S, Lin C, Studholme C, DeCarli CS, Krueger G, Ward HA, Metzger GJ, Scott KT, Mallozzi R, Blezek D, Levy J, Debbins JP, Fleisher AS, Albert M, Green R, Bartzokis G, Glover G, Mugler J, Weiner MW. The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods. J Magn Reson Imaging. 2008;27:685–691. - PMC - PubMed
    1. Panagyres PK. The contribution of the study of neurodegenerative disorders to the understanding of human memory. QJM. 2004;97:555–567. - PubMed
    1. Fox NC, Warrington EK, Seiffer AL, Agnew SK, Rossor MN. Presymptomatic cognitive deficits in individuals at risk of familial Alzheimer's disease. A longitudinal prospective study. Brain. 1998;121:1631–1639. - PubMed
    1. Killiany RJ, Gomez-Isla T, Moss M, Kikinis R, Sandor T, Jolesz F, Tanzi R, Jones K, Hyman BT, Albert MS. Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease. Ann Neurol. 2000;47:430–439. - PubMed

LinkOut - more resources